{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:16:25Z","timestamp":1788376585737,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vranos Family Foundation Career Development Award in Prostate Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>[177Lu]Lu-PSMA-617 (LuPSMA) improves survival and quality of life in men with metastatic castration-resistant prostate cancer but requires substantial healthcare involvement. Our analysis evaluated the time toxicity associated with LuPSMA, representing the first dedicated radioligand time toxicity assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a multi-institutional retrospective study of patients initiating LuPSMA between April 2022 and March 2023. Patients were followed from first LuPSMA administration until 3\u2009months after the final cycle, initiation of new systemic therapy, or death. Time toxicity was quantified as healthcare contact days during the at-risk interval. Associations with baseline characteristics were evaluated using negative binomial regression models. Univariate and multivariable models were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of 135 patients included in the study was 69\u2009years, and the median prior systemic therapies was 4. Patients completed a median of 5 LuPSMA cycles over 7.6\u2009months. Median healthcare contact days were 20 (IQR, 15-28), representing 9.5% (IQR, 6.4-13.9) of at-risk days. Fifteen patients (11%) experienced high time toxicity (&amp;gt;1 contact day per 5\u2009days), while 42 (31%) had low time toxicity (\u22641 contact day per 14\u2009days). Among the 57 patients who received both cycle 1 and cycle 6, the mean per cycle healthcare contact days were 4 and 3.6, respectively (paired Wilcoxon signed-rank test, P\u2009=\u2009.04). Routine oncology visits comprised 32.7% of contact days, compared with 8.8% from hospitalizations. Lower baseline hemoglobin was independently associated with greater time toxicity (RR = 0.87; 95% CI, 0.79-0.96; P\u2009=\u2009.004).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In heavily pretreated patients, LuPSMA demonstrated relatively low time toxicity, supporting it as a time-efficient therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag327","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:12:26Z","timestamp":1786705946000},"source":"Crossref","is-referenced-by-count":0,"title":["An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6686-4721","authenticated-orcid":false,"given":"Zachary","family":"Scharf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7268-5077","authenticated-orcid":false,"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4664-9296","authenticated-orcid":false,"given":"Elizabeth","family":"Tchitchkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-6033","authenticated-orcid":false,"given":"Avina","family":"Rami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brigham and Women\u2019s Hospital , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J","family":"Orme","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0086-0556","authenticated-orcid":false,"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-078X","authenticated-orcid":false,"given":"Heather A","family":"Jacene","sequence":"additional","affiliation":[{"name":"Department of Imaging, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-0888","authenticated-orcid":false,"given":"Daniel","family":"Sentana-Lledo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2836","authenticated-orcid":false,"given":"Daniel S","family":"Childs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026090214420022900_oyag327-B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/MOU.0000000000001234","article-title":"Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: current status and future prospects","volume":"35","author":"Wong","year":"2025","journal-title":"Curr Opin Urol"},{"key":"2026090214420022900_oyag327-B2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026090214420022900_oyag327-B3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data","volume":"65","author":"Murthy","year":"2024","journal-title":"J Nucl Med"},{"key":"2026090214420022900_oyag327-B4","doi-asserted-by":"publisher","first-page":"102398","DOI":"10.1016\/j.clgc.2025.102398","article-title":"Safety and efficacy of lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Belabaci","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"2026090214420022900_oyag327-B5","first-page":"T3","article-title":"Practical treatment of lutetium-177 vipivotide tetraxetan (pluvicto) in a clinical setting","volume":"64","author":"Gonzalez","year":"2023","journal-title":"J Nucl Med"},{"key":"2026090214420022900_oyag327-B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","article-title":"Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"},{"key":"2026090214420022900_oyag327-B7","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","article-title":"Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"51","author":"Song","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090214420022900_oyag327-B8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.trecan.2023.01.006","article-title":"The unequal burden of time toxicity","volume":"9","author":"Johnson","year":"2023","journal-title":"Trends Cancer"},{"key":"2026090214420022900_oyag327-B9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00520-024-08844-1","article-title":"Time toxicity among older patients with cancer treated with palliative systemic therapy","volume":"32","author":"Baltussen","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026090214420022900_oyag327-B10","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026090214420022900_oyag327-B11","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf046","article-title":"Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life","volume":"30","author":"Sentana-Lledo","year":"2025","journal-title":"Oncologist"},{"key":"2026090214420022900_oyag327-B12","author":"Urbaniak","year":"2013"},{"key":"2026090214420022900_oyag327-B13","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1200\/JOP.19.00328","article-title":"Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"16","author":"Bange","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026090214420022900_oyag327-B14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/OP.23.00811","article-title":"Time toxicity experienced by early-phase cancer clinical trial participants","volume":"20","author":"Durbin","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026090214420022900_oyag327-B15","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.2967\/jnumed.124.268277","article-title":"Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [177Lu]Lu-PSMA-617","volume":"65","author":"Muniz","year":"2024","journal-title":"J Nucl Med"},{"key":"2026090214420022900_oyag327-B16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41391-025-01034-y","article-title":"Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"29","author":"Yanagisawa","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026090214420022900_oyag327-B17","doi-asserted-by":"publisher","first-page":"e2547930","DOI":"10.1001\/jamanetworkopen.2025.47930","article-title":"Time toxicity of cancer care: a call to action","volume":"8","author":"Doshi","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026090214420022900_oyag327-B18","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JOP.18.00254","article-title":"Unplanned hospitalization among individuals with cancer in the year after diagnosis","volume":"15","author":"Whitney","year":"2019","journal-title":"J Oncol Pract"},{"key":"2026090214420022900_oyag327-B19","doi-asserted-by":"publisher","first-page":"e0213209","DOI":"10.1371\/journal.pone.0213209","article-title":"Time to initial cancer treatment in the United States and association with survival over time: an observational study","volume":"14","author":"Khorana","year":"2019","journal-title":"PLoS One"},{"key":"2026090214420022900_oyag327-B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026090214420022900_oyag327-B21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026090214420022900_oyag327-B22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag327\/70666035\/oyag327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag327\/70666035\/oyag327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag327\/70666035\/oyag327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:42:09Z","timestamp":1788374529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag327\/8762640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag327","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag327"}}